| # | Title | Journal | Year | Citations |
|---|
|
| 1 | Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis | Journal of Clinical Oncology | 2014 | 535 |
| 2 | Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention | Circulation | 2019 | 479 |
| 3 | Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk | European Heart Journal | 2019 | 364 |
| 4 | Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease | Journal of the American College of Cardiology | 2015 | 286 |
| 5 | Critical roles of inflammation in atherosclerosis | Journal of Cardiology | 2019 | 236 |
| 6 | Quantitative Comparison of Intracellular Trafficking and Nuclear Transcription between Adenoviral and Lipoplex Systems | Molecular Therapy | 2006 | 208 |
| 7 | Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition | Cancer Research | 2013 | 196 |
| 8 | Altered Cholesterol Metabolism in Niemann-Pick Type C1 Mouse Brains Affects Mitochondrial Function | Journal of Biological Chemistry | 2005 | 185 |
| 9 | From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients | Clinical Pharmacology and Therapeutics | 2015 | 160 |
| 10 | New Japanese Initiatives on Stem Cell Therapies | Cell Stem Cell | 2015 | 112 |
| 11 | Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies | Lancet Haematology,the | 2018 | 107 |
| 12 | Cryo-EM structures of the human volume-regulated anion channel LRRC8 | Nature Structural and Molecular Biology | 2018 | 106 |
| 13 | Expansion of Functional Human Mucosal-Associated Invariant T Cells via Reprogramming to Pluripotency and Redifferentiation | Cell Stem Cell | 2013 | 90 |
| 14 | Master protocol trials in oncology: Review and new trial designs | Contemporary Clinical Trials Communications | 2018 | 87 |
| 15 | Fiber-Modified Adenovirus Vectors Decrease Liver Toxicity through Reduced IL-6 Production | Journal of Immunology | 2007 | 72 |
| 16 | Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective | Nature Reviews Drug Discovery | 2013 | 67 |
| 17 | Successful bridging strategy based on ICH E5 guideline for drugs approved in Japan | Clinical Pharmacology and Therapeutics | 2005 | 65 |
| 18 | New Governmental Regulatory System for Stem Cell—Based Therapies in Japan | Therapeutic Innovation and Regulatory Science | 2014 | 65 |
| 19 | General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation | Journal of Controlled Release | 2015 | 65 |
| 20 | Modified Adenoviral Vectors Ablated for Coxsackievirus–Adenovirus Receptor,αv Integrin, and Heparan Sulfate Binding ReduceIn VivoTissue Transduction and Toxicity | Human Gene Therapy | 2006 | 62 |
| 21 | Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan | Clinical Pharmacology and Therapeutics | 2014 | 62 |
| 22 | Japanese registry for Mechanically Assisted Circulatory Support: First report | Journal of Heart and Lung Transplantation | 2017 | 62 |
| 23 | Establishment of the MID‐NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan | Pharmacoepidemiology and Drug Safety | 2019 | 56 |
| 24 | Angiogenesis, Cancer, and Vascular Aging | Frontiers in Cardiovascular Medicine | 2017 | 54 |
| 25 | Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities | Gene Therapy | 2005 | 49 |
| 26 | Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response Factors | Clinical Pharmacology and Therapeutics | 2010 | 49 |
| 27 | Heart Failure Clinical Trials in East and Southeast Asia | JACC: Heart Failure | 2016 | 49 |
| 28 | Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development | Drug Metabolism and Pharmacokinetics | 2019 | 49 |
| 29 | Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon | Gene Therapy | 2007 | 48 |
| 30 | Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium | Circulation | 2023 | 48 |
| 31 | Present State of New Chiral Drug Development and Review in Japan | Journal of Health Science | 2008 | 45 |
| 32 | Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients | Clinical Pharmacokinetics | 2010 | 45 |
| 33 | Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole | Scientific Reports | 2017 | 42 |
| 34 | Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI | Journal of the American College of Cardiology | 2020 | 42 |
| 35 | Communication of Radiation-Induced Signals in Vivo between DNA Repair Deficient and Proficient Medaka (Oryzias latipes) | Environmental Science & Technology | 2009 | 40 |
| 36 | Regulatory Challenges in the Review of Data from Global Clinical Trials: The PMDA Perspective | Clinical Pharmacology and Therapeutics | 2013 | 40 |
| 37 | Adenovirus serotype 35 vector-mediated transduction into human CD46-transgenic mice | Gene Therapy | 2006 | 39 |
| 38 | Structured Frameworks to Increase the Transparency of the Assessment of Benefits and Risks of Medicines: Current Status and Possible Future Directions | Clinical Pharmacology and Therapeutics | 2015 | 38 |
| 39 | Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine | Regenerative Therapy | 2016 | 38 |
| 40 | Novel action of apolipoprotein E (ApoE): ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons | Molecular Neurodegeneration | 2007 | 37 |
| 41 | Vaccination with Antigen-Transfected, NKT Cell Ligand–Loaded, Human Cells Elicits Robust In Situ Immune Responses by Dendritic Cells | Cancer Research | 2013 | 37 |
| 42 | The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health | Clinical Pharmacology and Therapeutics | 2011 | 36 |
| 43 | An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies | Clinical Cancer Research | 2015 | 36 |
| 44 | The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States | Therapeutic Innovation and Regulatory Science | 2017 | 36 |
| 45 | Regulation of traditional herbal medicinal products in Japan | Journal of Ethnopharmacology | 2014 | 35 |
| 46 | First Approval of Regenerative Medical Products under the PMD Act in Japan | Cell Stem Cell | 2016 | 35 |
| 47 | An adaptive dose‐finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials | Statistics in Medicine | 2012 | 34 |
| 48 | ‘All In’: a pragmatic framework for COVID‐19 testing and action on a global scale | EMBO Molecular Medicine | 2020 | 34 |
| 49 | Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report | Journal of Pharmaceutical Sciences | 2021 | 34 |
| 50 | Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma | Oncologist | 2021 | 34 |
